{"id":"https://openalex.org/W2987508808","doi":"https://doi.org/10.1007/s40261-019-00869-3","title":"Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis","display_name":"Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis","publication_year":2019,"publication_date":"2019-11-02","ids":{"openalex":"https://openalex.org/W2987508808","doi":"https://doi.org/10.1007/s40261-019-00869-3","mag":"2987508808","pmid":"https://pubmed.ncbi.nlm.nih.gov/31679121","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6989620"},"language":"en","primary_location":{"id":"doi:10.1007/s40261-019-00869-3","doi":"https://doi.org/10.1007/s40261-019-00869-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-019-00869-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00869-3.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00869-3.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064425810","display_name":"Qiao Liu","orcid":"https://orcid.org/0000-0001-8739-6236","observed_orcids":["https://orcid.org/0000-0001-8739-6236"]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Qiao Liu","raw_affiliation_strings":["Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100551841","display_name":"Xia Luo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xia Luo","raw_affiliation_strings":["Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101639683","display_name":"Liubao Peng","orcid":"https://orcid.org/0000-0001-6155-0709","observed_orcids":["https://orcid.org/0000-0001-6155-0709"]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Liubao Peng","raw_affiliation_strings":["Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113932007","display_name":"Lidan Yi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Lidan Yi","raw_affiliation_strings":["Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112129019","display_name":"Xiaomin Wan","orcid":"https://orcid.org/0000-0001-5315-8141","observed_orcids":["https://orcid.org/0000-0001-5315-8141"]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Xiaomin Wan","raw_affiliation_strings":["Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015533842","display_name":"Xiaohui Zeng","orcid":"https://orcid.org/0000-0001-6050-4137","observed_orcids":["https://orcid.org/0000-0001-6050-4137"]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xiaohui Zeng","raw_affiliation_strings":["PET-CT Center, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China. zengxiaohui2008@csu.edu.cn","PET-CT Center, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PET-CT Center, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China. zengxiaohui2008@csu.edu.cn","institution_ids":["https://openalex.org/I4210153856"]},{"raw_affiliation_string":"PET-CT Center, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101555998","display_name":"Chongqing Tan","orcid":"https://orcid.org/0000-0002-6007-4170","observed_orcids":["https://orcid.org/0000-0002-6007-4170","https://orcid.org/0000-0002-0852-1236"]},"institutions":[{"id":"https://openalex.org/I4210153856","display_name":"Second Xiangya Hospital of Central South University","ror":"https://ror.org/053v2gh09","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210153856"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Chongqing Tan","raw_affiliation_strings":["Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China. tanchongqing@csu.edu.cn","Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China"],"raw_orcid":"https://orcid.org/0000-0002-6007-4170","affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China. tanchongqing@csu.edu.cn","institution_ids":["https://openalex.org/I4210153856"]},{"raw_affiliation_string":"Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, People's Republic of China","institution_ids":["https://openalex.org/I4210153856"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5015533842","https://openalex.org/A5101555998"],"corresponding_institution_ids":["https://openalex.org/I4210153856"],"apc_list":{"value":3140,"currency":"USD","value_usd":3140},"apc_paid":{"value":3140,"currency":"USD","value_usd":3140},"fwci":7.7739,"has_fulltext":true,"cited_by_count":49,"citation_normalized_percentile":{"value":0.97269871,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"40","issue":"2","first_page":"129","last_page":"137"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.008299999870359898,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9929999709129333},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8109999895095825},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9129999876022339},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9160000085830688},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8050000071525574},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8199999928474426},{"id":"https://openalex.org/keywords/chinese-healthcare-system","display_name":"Chinese healthcare system","score":0.6449999809265137},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.5709999799728394},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.44699999690055847},{"id":"https://openalex.org/keywords/willingness-to-pay-threshold","display_name":"willingness-to-pay threshold","score":0.6370000243186951},{"id":"https://openalex.org/keywords/parametric-survival-models","display_name":"parametric survival models","score":0.6740000247955322},{"id":"https://openalex.org/keywords/patient-age-and-sex-differences","display_name":"patient age and sex differences","score":0.453000009059906},{"id":"https://openalex.org/keywords/us-china-comparison","display_name":"China\u2013United States comparison","score":0.3089999854564667}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9191527366638184},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8932579755783081},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.8696032762527466},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.7494117021560669},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6774433851242065},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.5384933948516846},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4595751464366913},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3632850646972656},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3378893733024597},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.13785064220428467}],"mesh":[{"descriptor_ui":"D000077143","descriptor_name":"Docetaxel","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000077143","descriptor_name":"Docetaxel","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008390","descriptor_name":"Markov Chains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s40261-019-00869-3","doi":"https://doi.org/10.1007/s40261-019-00869-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-019-00869-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00869-3.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6989620","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6989620","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Drug Investig","raw_type":"Text"},{"id":"pmid:31679121","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31679121","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical drug investigation","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1007/s40261-019-00869-3","doi":"https://doi.org/10.1007/s40261-019-00869-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40261-019-00869-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40261-019-00869-3.pdf","source":{"id":"https://openalex.org/S138241747","display_name":"Clinical Drug Investigation","issn_l":"0114-2402","issn":["0114-2402","1173-2563","1179-1918","2196-4920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Drug Investigation","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2109918530","display_name":"\u57fa\u4e8eRAC-E\u5206\u6790\u5efa\u7acbPET-CT\u7528\u4e8e\u80bf\u7624\u5206\u671f\u8bca\u65ad\u7684\u536b\u751f\u7ecf\u6d4e\u5b66\u8bc4\u4ef7\u6846\u67b6","funder_award_id":"81401547","funder_id":"https://openalex.org/F4320321001","funder_display_name":"National Natural Science Foundation of China"},{"id":"https://openalex.org/G3356323814","display_name":null,"funder_award_id":"81603081","funder_id":"https://openalex.org/F4320321001","funder_display_name":"National Natural Science Foundation of China"}],"funders":[{"id":"https://openalex.org/F4320321001","display_name":"National Natural Science Foundation of China","ror":"https://ror.org/01h0zpd94"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2987508808.pdf","grobid_xml":"https://content.openalex.org/works/W2987508808.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W1977373411","https://openalex.org/W1996652550","https://openalex.org/W2005295931","https://openalex.org/W2049034349","https://openalex.org/W2061932411","https://openalex.org/W2077633559","https://openalex.org/W2137210918","https://openalex.org/W2158646284","https://openalex.org/W2163351155","https://openalex.org/W2272984102","https://openalex.org/W2293531514","https://openalex.org/W2296800272","https://openalex.org/W2306359401","https://openalex.org/W2510870255","https://openalex.org/W2783091042","https://openalex.org/W2790743957","https://openalex.org/W2791043965","https://openalex.org/W2794945244","https://openalex.org/W2801738355","https://openalex.org/W2828795140","https://openalex.org/W2896549747","https://openalex.org/W2905203381","https://openalex.org/W2908684819","https://openalex.org/W2910187760","https://openalex.org/W2915456024","https://openalex.org/W2919091706","https://openalex.org/W2924630395","https://openalex.org/W2946863839","https://openalex.org/W2953812684","https://openalex.org/W4250935139","https://openalex.org/W4323808989"],"related_works":["https://openalex.org/W3027139849","https://openalex.org/W4323808989","https://openalex.org/W4313388450","https://openalex.org/W7166745287","https://openalex.org/W4406147786","https://openalex.org/W2956006889","https://openalex.org/W4200374841","https://openalex.org/W4293102128","https://openalex.org/W2953812684","https://openalex.org/W3196036191"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVE:":[2],"The":[3,69],"economic":[4],"assessment":[5],"of":[6,32,51,64,71,79,101,114,122,205,227,244,302,358],"immuno-oncology":[7],"agents":[8],"in":[9,38,60,62,83,118,264,339,346,363],"Chinese":[10,92],"patients":[11,89,140,297,310,313,333],"is":[12,21,54,324,344],"limited":[13],"despite":[14],"a":[15,225,355],"need":[16],"for":[17,28,87,187,296,332],"new":[18],"therapies.":[19],"Nivolumab":[20,218,323],"the":[22,29,48,77,84,91,109,119,130,182,203,206,235,242,253,285,347],"first":[23],"immune":[24],"checkpoint":[25],"inhibitor":[26],"approved":[27],"second-line":[30,85,120],"treatment":[31,121,361],"non-small":[33],"cell":[34],"lung":[35],"cancer":[36],"(NSCLC)":[37],"China,":[39],"and":[40,67,112,149,161,166,171,173,190,195,252,272,312],"it":[41,53],"significantly":[42],"prolongs":[43],"overall":[44,273],"survival.":[45],"However,":[46],"considering":[47],"high":[49],"cost":[50,111,226],"nivolumab,":[52],"urgent":[55],"to":[56,75,107,147,201,237,241,326],"assess":[57],"its":[58],"value":[59],"China":[61],"terms":[63],"both":[65],"efficacy":[66],"cost.":[68],"objective":[70],"this":[72],"study":[73],"was":[74,105,127,293],"investigate":[76],"cost-effectiveness":[78],"nivolumab":[80,115,245,292,343],"vs":[81,116],"docetaxel":[82,117,331],"setting":[86],"NSCLC":[88,123,338],"from":[90,129,142],"healthcare":[93],"system":[94],"perspective.":[95],"METHODS:":[96],"A":[97],"Markov":[98],"model":[99,286],"consisting":[100],"three":[102],"health":[103,167],"states,":[104],"designed":[106],"evaluate":[108],"lifetime":[110],"effectiveness":[113],"patients.":[124],"Clinical":[125],"data":[126,152],"derived":[128],"CheckMate":[131],"078":[132],"phase":[133],"III":[134],"clinical":[135,157],"trial,":[136],"which":[137],"included":[138,345],"504":[139],"predominantly":[141],"China.":[143,340,364],"Parametric":[144],"survival":[145,151,266,274],"models":[146],"fit":[148,160],"extrapolate":[150],"were":[153,169,179,199,211,299],"chosen":[154],"based":[155],"on":[156,284],"rationality,":[158],"visual":[159],"statistical":[162],"goodness-of-fit.":[163],"Lifetime":[164],"costs":[165],"outcomes":[168],"calculated,":[170],"US$28,899":[172],"$63,564":[174],"per":[175,229,246],"quality-adjusted":[176],"life-year":[177],"(QALY)":[178],"selected":[180],"as":[181],"willingness-to-pay":[183],"(WTP)":[184],"threshold":[185],"values":[186,263],"general":[188],"regions":[189],"affluent":[191],"regions,":[192],"respectively.":[193],"One-way":[194],"probabilistic":[196],"sensitivity":[197],"analyses":[198,210,232,289],"undertaken":[200],"explore":[202],"robustness":[204],"model.":[207],"Additional":[208],"subgroup":[209],"performed.":[212],"RESULTS:":[213],"In":[214],"base":[215],"case":[216],"analysis,":[217],"yielded":[219],"an":[220],"additional":[221],"0.24":[222],"QALYs,":[223],"at":[224,318],"$93,307":[228],"QALY.":[230],"Sensitivity":[231],"suggested":[233],"that":[234,291,342],"results":[236],"be":[238,327,354],"most":[239,294],"sensitive":[240],"price":[243],"kg":[247],"(mean":[248,268],"$60.00;":[249],"range":[250,259,270],"$26.00-$60.00)":[251],"mean":[254,357],"patient":[255],"weight":[256],"(65":[257],"kg,":[258],"52-78":[260],"kg).":[261],"Utility":[262],"progression-free":[265],"state":[267],"0.804;":[269],"0.643-0.965)":[271],"hazard":[275],"ratio":[276],"(0.68;":[277],"97.7%":[278],"CI":[279],"0.52-0.90)":[280],"had":[281],"moderate":[282],"impact":[283],"results.":[287],"Subgroup":[288],"indicated":[290],"cost-effective":[295,328],"who":[298],"65":[300],"years":[301],"age":[303],"or":[304],"older":[305],"($85,171/QALY),":[306],"followed":[307],"by":[308],"female":[309],"($85,273/QALY)":[311],"with":[314,330,334],"tumor":[315],"PD-L1":[316],"expression":[317],"least":[319],"1%":[320],"($90,309/QALY).":[321],"CONCLUSIONS:":[322],"unlikely":[325],"compared":[329],"previously":[335],"treated":[336],"advanced":[337],"Ensuring":[341],"National":[348],"Reimbursement":[349],"Drug":[350],"List":[351],"(NRDL)":[352],"may":[353],"valid":[356],"meeting":[359],"extensive":[360],"demands":[362]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2019-11-22T00:00:00"}